Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma

Se Hoon Park1, Yuna Lee1, Sang Hoon Han1, So Young Kwon2, Oh Sang Kwon2, Sun Suk Kim2, Ju Hyun Kim2, Yeon Ho Park3, Jeong Nam Lee3, Soo-Mee Bang1, Eun Kyung Cho1, Dong Bok Shin1* and Jae Hoon Lee1

Author Affiliations

1 Division of Hematology and Oncology, Department of Medicine, Gachon Medical School Gil Medical Center, Incheon 405-760, Korea

2 Division of Gastroenterology, Department of Medicine, Gachon Medical School Gil Medical Center, Incheon 405-760, Korea

3 Department of General Surgery, Gachon Medical School Gil Medical Center, Incheon 405-760, Korea

For all author emails, please log on.

BMC Cancer 2006, 6:3  doi:10.1186/1471-2407-6-3

Published: 5 January 2006

Abstract

Background

Although numerous chemotherapeutic agents have been tested, the role of systemic chemotherapy for hepatocellular carcinoma (HCC) has not been clarified. New therapeutic strategies are thus needed to improve outcomes, and we designed this study with new effective drug combination.

Methods

Twenty-nine patients with histologically-confirmed, metastatic HCC received a combination chemotherapy with doxorubicin 60 mg/m2 and cisplatin 60 mg/m2 on day 1, plus capecitabine 2000 mg/m2/day as an intermittent regimen of 2 weeks of treatment followed by a 1-week rest.

Results

The median age was 49 years (range, 32–64) and 19 patients were hepatitis B virus seropositive. Child-Pugh class was A in all patients and 4 had Zubrod performance status of 2. The objective response rate was 24% (95% CI 9–40) with 6 stable diseases. The chemotherapy was generally well tolerated despite one treatment-related death.

Conclusion

Combination chemotherapy with doxorubicin, cisplatin and capecitabine produced modest antitumor activity with tolerable adverse effects in patients with metastatic HCC.